Syntara Limited (PMXSF) Discusses Preliminary Phase II Results for SNT-4728 in Isolated REM Sleep Behavior Disorder Transcript

Matthew Wright

Thanks for standing by and welcome to the Syntara Investor Webinar and Q&A for this morning’s announcement of the preliminary analysis of the Phase II trial of SNT-4728. [Operator Instructions]

On the webinar from Syntara, we have the CEO, Gary Phillips; and the Chief Medical Officer, Jana Baskar. And joining them are Simon Lewis, who’s a neurologist and the trial’s principal investigator. He’s also the Director of Parkinson’s Disease Research Clinic at Macquarie University.

To begin, I’ll hand it over to Gary. Please go ahead.

Gary Phillips
CEO, MD & Director

Thanks very much, Matt, and welcome, everybody, and thank you for bearing us some time today. Matt just introduced the 3 people on there. So we’ve asked Simon to come along and join us because we understand that this study is — it was a technically challenging study, and being the first study of its type studying a medication like iRBD. There’s a lot to unpack and think about as we move forward.

And I think just at the outset, I’d also say this for Syntara shareholders, this was a study that was fully funded by Parkinson’s U.K. We’re very grateful to them for their support in getting us to this point. And Professor Lewis, Professor Ho from the U.K. were instrumental really in pursuing and building the design of this study. and in front of Parkinson’s U.K. and other philanthropic bodies and getting the funding for this. So this is a great outcome that we’ve had today as the first set of information coming out of this study.